Arizona Clinical Trials Report — June 2026

For Arizonans considering participation in clinical research, June 2026 presents a critical window of opportunity, particularly for trials nearing their conclusion. Across the state, 95 clinical trials are slated to close within the next 90 days, meaning time is running out to enroll. This includes 13 studies actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

Individuals living with certain health conditions should also act quickly to explore trials with impending deadlines. Research focusing on mental health, liver conditions, and cardiovascular issues are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Major depressive disorder
• End stage liver disease
• Tricuspid regurgitation
• Hepatic impairment
• Alzheimer's disease
• Acute myeloid leukemia
• Asthma
• Amyotrophic lateral sclerosis

New Horizons: Arizona Welcomes 33 New Clinical Trials

This month, Arizona welcomes 33 new clinical trials, a notable increase from the 27 trials that opened in May 2026. These new studies bring a fresh wave of opportunities, including several significant Phase 3 drug trials from major pharmaceutical companies, offering participants access to cutting-edge treatments for widespread health challenges like obesity, type 2 diabetes, and migraine.

The most common conditions addressed by these new studies include:

• Obesity
• Type 2 diabetes mellitus
• Overweight
• Chronic weight management
• Chronic pain

In terms of intervention types, drug trials lead the way, accounting for 20 of the new studies. Device trials are also well-represented with 6 new initiatives, alongside other types of research including combination products, diagnostic tests, behavioral interventions, and dietary supplements.

Spotlight on Major Phase 3 Drug Trials

Several prominent pharmaceutical companies have launched large-scale Phase 3 trials in Arizona this month, focusing on conditions affecting millions. These studies represent advanced stages of research, often comparing new treatments against existing ones or placebo to confirm efficacy and safety.

• AstraZeneca is sponsoring NCT07667803, a Phase 3 "Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM." This substantial global study aims to enroll 4,500 participants, evaluating a new treatment for weight management and type 2 diabetes.
• Another major Phase 3 trial, NCT07654361, is "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)," sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. This global study seeks 3,600 participants to assess the long-term efficacy and safety of aleniglipron.
• For those with type 2 diabetes, AstraZeneca is also sponsoring NCT07662213, a Phase 3 study to find out if "Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide." This trial plans for 1,200 participants. Another AstraZeneca Phase 3 study, NCT07662135, will investigate elecoglipron in 900 adults with type 2 diabetes and impaired renal function.
• Individuals experiencing migraines may be interested in NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine," a Phase 3 trial sponsored by Kallyope Inc., targeting 1,800 participants. Kallyope Inc. is also conducting a long-term safety study for the same drug, NCT07674654, enrolling 1,000 participants.
• Gasherbrum Bio, Inc. is also leading NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)," a Phase 3 trial enrolling 1,100 participants.
• A unique study, NCT07643896, "The ADVANCE Study," sponsored by BillionToOne Inc., aims to enroll 1,000 participants to demonstrate a novel non-invasive circulating fetal cell (CFC) based approach to prenatal risk assessment.

Geographic Reach: Research Opportunities Across Arizona

Arizona's clinical research landscape continues to be robust, with 1,687 clinical trials currently recruiting across 43 cities and 1,111 research sites statewide. This month, new research initiatives are concentrated in several key metropolitan areas, ensuring broad access for residents.

The majority of new trials opened in:

• Phoenix (17 new trials)
• Chandler (6 new trials)
• Tucson (6 new trials)
• Peoria (3 new trials)
• Tempe (3 new trials)
• Scottsdale (3 new trials)

Additional opportunities are also available in Sun City West, Surprise, Glendale, and Mesa. This distribution ensures that residents in various regions of Arizona have access to cutting-edge research, with major cities serving as central hubs for clinical investigations.

Healthy Volunteers and Diverse Participation

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 33 new trials launched this month, 4 are actively seeking healthy volunteers. Statewide, a total of 148 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Clinical trials in Arizona are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 2 include children as participants, and 27 include older adults, ensuring that research benefits diverse age groups. While 2 trials are female-only and 1 is male-only, the vast majority are open to both genders. Academic institutions like Arizona State University and the University of Arizona are sponsoring 2 new trials each, while industry sponsors are driving significant research efforts, with 24 new trials sponsored by pharmaceutical companies such as AstraZeneca, Eli Lilly and Company, Kallyope Inc., and Gasherbrum Bio, Inc.

As we move through June, the focus will remain on the ongoing enrollment in these significant Phase 3 trials and the exploration of new treatments, diagnostics, and preventive measures for a broad spectrum of health challenges across Arizona. We encourage interested individuals to explore these opportunities, especially those with impending deadlines, to contribute to the future of medicine.